ArticleNeurocritical care2025
Nimodipine in Aneurysmal Subarachnoid Hemorrhage: Are Old Data Enough to Justify Its Current Treatment Regimen?
Article in Neurocritical care, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- A Novel Anti-Inflammatory Small Molecule MW189 Reduces Microglial Activation and Improves Functional Outcomes in a Murine Model of Subarachnoid Hemorrhage.Neurocritical care · 2026Article
- Oral Nimodipine in Aneurysmal Subarachnoid Hemorrhage: A Critical Propensity Score-Matched Reevaluation in a Contemporary Cohort.Neurology and therapy · 2026Article
- Commentary on: "Impact of Nimodipine-Induced Blood Pressure Reductions on Cerebral Autoregulation and Functional Outcome after Aneurysmal Subarachnoid Hemorrhage".Neurocritical care · 2026Article
- Machine Learning-Identified Potential Interaction Between Clazosentan and Nicardipine in Patients with Subarachnoid Hemorrhage.Journal of clinical medicine · 2026Article
- Magnesium silicate nanosheets enable sustained hydrogen release to attenuate secondary brain injury following intracerebral hemorrhage.Journal of translational medicine · 2026Article
- Early dexmedetomidine and postoperative RASS-defined examinability after microsurgical clipping for aneurysmal subarachnoid hemorrhage: a time-resolved 24-h landmark cohort study.Frontiers in neurology · 2026Article
- High risk and low incidence diseases: Aneurysmal subarachnoid hemorrhage.The American journal of emergency medicine · 2025Review
- Acute Neurovascular Inflammatory Profile in Patients with Aneurysmal Subarachnoid Hemorrhage.Biomolecules · 2025Article
- Comment on shortened treatment with nimodipine in aneurysmal subarachnoid hemorrhage.Brain & spine · 2025Article
- Pathophysiological mechanisms underlying early brain injury and delayed cerebral ischemia in the aftermath of aneurysmal subarachnoid hemorrhage: a comprehensive analysis.Frontiers in neurology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nimodipine, a dihydropyridine L-type calcium channel antagonist, constitutes one of the mainstays of care to prevent delayed cerebral ischemia in patients with aneurysmal subarachnoid hemorrhage (aSAH) because it has been associated with a reduction in infarction rates and improvement in functional outcomes despite not significantly preventing angiographic vasospasm. Although it is a widely accepted treatment, controversies surrounding the current regimen of nimodipine in patients with aSAH exist. Still, there is a wide space open for randomized controlled trials or alternative study designs comparing different routes of administration, dosing, and timing of nimodipine treatment regimen in patients with aSAH.
Indexed as
Identifiers
39690377What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.